cabenuva
Selected indexed studies
- Cabenuva: A breakthrough in HIV/AIDS treatment. (J Pak Med Assoc, 2023) [PMID:36932803]
- Cabotegravir/rilpivirine (Cabenuva) for HIV-1 infection. (Med Lett Drugs Ther, 2021) [PMID:34180282]
- Rilpivirine. (, 2006) [PMID:30000877]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Cabotegravir Plus Rilpivirine: First Approval. (2020) pubmed
- Cabenuva: A breakthrough in HIV/AIDS treatment. (2023) pubmed
- Cabotegravir/rilpivirine (Cabenuva) for HIV-1 infection. (2021) pubmed
- Rilpivirine. (2006) pubmed
- Cabotegravir. (2006) pubmed
- PMID:33439593 (2020) pubmed
- PMID:33443991 (2020) pubmed
- Cabenuva®: Differentiated service delivery and the community Pharmacists' roles in achieving UNAIDS 2030 target in Nigeria. (2021) pubmed
- PMID:33439592 (2020) pubmed
- Design strategies for long-acting anti-HIV pharmaceuticals. (2020) pubmed